99 related articles for article (PubMed ID: 38644454)
1. FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N; Karmastaji S; Matic A; Bril V
CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
[TBL] [Abstract][Full Text] [Related]
2. Efgartigimod in refractory autoimmune myasthenia gravis.
Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
Muscle Nerve; 2024 Jun; ():. PubMed ID: 38899431
[TBL] [Abstract][Full Text] [Related]
3. Efgartigimod in the treatment of Guillain-Barré syndrome.
Zhang H; Ma J; Feng Y; Ma H; Liu D; Pang X; Chang X; Zhao R; Wang J; Guo J; Zhang W
J Neurol; 2024 Jun; 271(6):3506-3511. PubMed ID: 38532142
[TBL] [Abstract][Full Text] [Related]
4. Real-World experience with efgartigimod in patients with myasthenia gravis.
Fuchs L; Shelly S; Vigiser I; Kolb H; Regev K; Schwartzmann Y; Vaknin-Dembinsky A; Dori A; Karni A
J Neurol; 2024 Jun; 271(6):3462-3470. PubMed ID: 38528163
[TBL] [Abstract][Full Text] [Related]
5. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control.
Konno S; Uchi T; Kihara H; Sugimoto H
Biomedicines; 2024 May; 12(6):. PubMed ID: 38927421
[TBL] [Abstract][Full Text] [Related]
6. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.
Zhang Z; Yang M; Luo T; Du X; Wang Z; Huang X; Zhang Y
Ther Adv Neurol Disord; 2024; 17():17562864241254895. PubMed ID: 38813520
[TBL] [Abstract][Full Text] [Related]
7. Efgartigimod infusion in the treatment regimen for myasthenic crisis: A case report.
Sun F; Batra A; Dickson D; Li Y; Wu EL
Muscle Nerve; 2024 Jun; ():. PubMed ID: 38850117
[No Abstract] [Full Text] [Related]
8. Efgartigimod as a novel FcRn inhibitor for autoimmune disease.
Yang Y; Shen Z; Shi F; Wang F; Wen N
Neurol Sci; 2024 Apr; ():. PubMed ID: 38644454
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
10. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
11. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
12. Efgartigimod alfa for the treatment of primary immune thrombocytopenia.
Broome C
Ther Adv Hematol; 2023; 14():20406207231172831. PubMed ID: 37188068
[TBL] [Abstract][Full Text] [Related]
13. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
